Evidence map›Paper›PMID 33564400›Full record

ArticleClinical kidney journal2021

Optimizing the timing of nephrology referral for patients with diabetic kidney disease.

Alberto Martínez-Castelao, María José Soler, José Luis Górriz Teruel, Juan F Navarro-González, Beatriz Fernandez-Fernandez, Fernando de Alvaro Moreno, Alberto Ortiz

Open access · goldAbstract readEditorial
In one paragraph

Article in Clinical kidney journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Alberto Martínez-CastelaoNephrology department, Bellvitge University Hospital, Barcelona, Spain.
María José SolerGEENDIAB (Grupo Español de Estudio de la Nefropatía Diabética), Sociedad Española Nefrología (SEN), Santander, Spain.
José Luis Górriz TeruelGEENDIAB (Grupo Español de Estudio de la Nefropatía Diabética), Sociedad Española Nefrología (SEN), Santander, Spain.
Juan F Navarro-GonzálezGEENDIAB (Grupo Español de Estudio de la Nefropatía Diabética), Sociedad Española Nefrología (SEN), Santander, Spain.
Beatriz Fernandez-FernandezREDinREN, Instituto Salud Carlos III, Madrid, Spain.
Fernando de Alvaro MorenoGEENDIAB (Grupo Español de Estudio de la Nefropatía Diabética), Sociedad Española Nefrología (SEN), Santander, Spain.
Alberto OrtizGEENDIAB (Grupo Español de Estudio de la Nefropatía Diabética), Sociedad Española Nefrología (SEN), Santander, Spain.
Instituto de Salud Carlos III · ESSociedad Española de Nefrología · ESINCLIVA Health Research Institute · ESUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-standardized rates of diabetes mellitus (DM)-related complications, such as acute myocardial infarction, stroke or amputations, have decreased in recent years, but this was not associated with a clear reduction of the incidence of advanced chronic kidney disease (CKD) requiring renal replacement therapy. The early detection of diabetic kidney disease (DKD) is a key to reduce complications, morbidity and mortality. Consensus documents and clinical practice guidelines recommend referral of DM patients to nephrology when the estimated glomerular filtration rate falls below 30 mL/min/1.73 m

Indexed as

diabetes mellitusdiabetic kidney diseasediabetic nephropathyearly referralmultidisciplinary care

Identifiers

PMID33564400
PMCPMC7857795
OpenAlexW3047189733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.